Table 1.

Toxicity, Outcomes, and Model Assumptions

Cancer Type	Toxicity
	Acute (%)						Late (%)
	IMRT			SBRT			IMRT			SBRT
	Zietman et al18	Zelefsky et al19	Storey et al20	King et al16	Boike et al17	Jabbari et al23	Zietman et al18	Zelefsky et al19	Kuban et al21	King et al16	Freeman et al22	King et al25
GU
RTOG grade
< 2	29	38	46	20	33	45	45	14	16	20	40	11
≥ 2	63	28	29	0	7	33	29	11	10	13	29	5
GI
RTOG grade
< 2	26	22	42	13	54	5	41	27	9	7	53	5
≥ 2	64	4	42	7	0	0	29	25	2	7	15	3

Study	Outcomes
	bPFS		PSA Failure Measurement
	Rate Range (%)	Survival (years)
Zietman et al18	91-98	5	PSA > 4
Kuban et al21	88-94	8	1996 ASTRO
Zelefsky et al19	86-92	3	1996 ASTRO
King et al25	92.7	5	Phoenix

Variable	Model Assumptions
	Baseline Value/Mean	SD	Range in Simulation	Distribution	Reference
Yearly transition rates
IMRT	0.02	0.01	0.0036-0.04	β	Zietman et al,18 Zelefsky et al,19 Kuban et al21
SBRT	0.02	0.01	0.0036-0.04	β	Freeman et al,22 Jabbari et al,23 King et al26
Hormone therapy	0.13	0.0219	0.06-0.019	β	Shipley et al27
Chemotherapy	1	—	—	—	Beekman et al28
Utility values
IMRT	0.9	0.05	0.8-1.0	β	Konski et al,24 Stewart et al29
SBRT	0.9	0.05	0.8-1.0	β	Konski et al,24 Stewart et al29
Hormone therapy	0.68	0.26	0.5-0.8	β	Bayoumi et al30
Chemotherapy	0.4	—	—	Uniform	Albertsen et al31
Costs
IMRT	$29,530	± 30%	$20,000-$40,000	Triangle	Konski et al,24 UTSW data
SBRT	$14,315	± 30%	$10,000-$20,000	Triangle	UTSW data
Hormone therapy	$7,200	$4,300	$2,000-$15,000	Normal	Red Book
Chemotherapy	$24,000	$15,000	$5,000-$100,000	Normal	Piper et al32

NOTE. Costs are expressed in 2010 US dollars; detailed cost analysis provided in Appendix Table A1, online only.

Abbreviations: ASTRO, American Society of Therapeutic Radiation Oncology; bPFS, biologic progression-free survival; GU, genitourinary; IMRT, intensity-modulated radiation therapy; PSA, prostate-specific antigen; RTOG, Radiation Therapy Oncology Group; SBRT, stereotactic body radiation therapy; SD, standard deviation; UTSW, University of Texas Southwestern.